Patient characteristics at start of lymphodepletion
| Parameter . | Total patients (n = 21) . |
|---|---|
| Age, median (range), y | 58 (24-67) |
| Sex, female/male | 6/15 |
| ECOG PS | |
| 0 | 3 |
| 1 | 15 |
| 2 | 3 |
| Diagnosis | |
| DLBCL | 18 |
| GCB/non-GCB/unknown | 5/9/4 |
| Transformed from follicular lymphoma, yes/no | 4/18 |
| CNS involvement, yes/no | 1/18 |
| Extranodal disease, yes/no | 10/18 |
| PMBCL | 3 |
| Bone marrow involvement, yes/no | 2/21 |
| Prior therapies | |
| Median (range) | 5 (3-8) |
| Number of prior therapies 3-4 | 8 |
| Number of prior therapies >4 | 13 |
| 1 prior autologous transplantation | 10 |
| 2 prior autologous transplantations | 2 |
| 1 prior allogeneic transplantation | 1 |
| Type of bridging therapy | |
| R-ICE | 5 |
| R-Pixantrone | 5 |
| R-GemOx | 4 |
| Irradiation | 1 |
| MTX + cytarabine | 1 |
| R-LEAM | 1 |
| Pembrolizumab | 1 |
| R-Polatuzumab | 1 |
| Bridging therapy, yes/no | 19/2 |
| Status at lymphodepletion | |
| CRP >30 ng/L, yes/no | 5/16 |
| Elevated IL-6, yes/no | 4/17 |
| Low platelet (<150/nL), yes/no | 10/11 |
| Elevated LDH, yes/no | 11/10 |
| IPI | |
| 0-2 | 13 |
| 3-5 | 8 |
| Days last chemotherapy to LD, median (range) | 26 (7-365) |
| Days apheresis to infusion, median (range) | 36 (32-47) |
| Ann Arbor score | |
| 0-II | 10 |
| III-IV | 11 |
| ZUMA-1 eligible | 2/21 |
| Reasons not eligible for ZUMA-1 | |
| Required bridging therapy | 19 |
| Platelets <75/nL | 6 |
| LVEF <50 | 6 |
| ECOG >1 | 3 |
| CNS disease | 1 |
| Parameter . | Total patients (n = 21) . |
|---|---|
| Age, median (range), y | 58 (24-67) |
| Sex, female/male | 6/15 |
| ECOG PS | |
| 0 | 3 |
| 1 | 15 |
| 2 | 3 |
| Diagnosis | |
| DLBCL | 18 |
| GCB/non-GCB/unknown | 5/9/4 |
| Transformed from follicular lymphoma, yes/no | 4/18 |
| CNS involvement, yes/no | 1/18 |
| Extranodal disease, yes/no | 10/18 |
| PMBCL | 3 |
| Bone marrow involvement, yes/no | 2/21 |
| Prior therapies | |
| Median (range) | 5 (3-8) |
| Number of prior therapies 3-4 | 8 |
| Number of prior therapies >4 | 13 |
| 1 prior autologous transplantation | 10 |
| 2 prior autologous transplantations | 2 |
| 1 prior allogeneic transplantation | 1 |
| Type of bridging therapy | |
| R-ICE | 5 |
| R-Pixantrone | 5 |
| R-GemOx | 4 |
| Irradiation | 1 |
| MTX + cytarabine | 1 |
| R-LEAM | 1 |
| Pembrolizumab | 1 |
| R-Polatuzumab | 1 |
| Bridging therapy, yes/no | 19/2 |
| Status at lymphodepletion | |
| CRP >30 ng/L, yes/no | 5/16 |
| Elevated IL-6, yes/no | 4/17 |
| Low platelet (<150/nL), yes/no | 10/11 |
| Elevated LDH, yes/no | 11/10 |
| IPI | |
| 0-2 | 13 |
| 3-5 | 8 |
| Days last chemotherapy to LD, median (range) | 26 (7-365) |
| Days apheresis to infusion, median (range) | 36 (32-47) |
| Ann Arbor score | |
| 0-II | 10 |
| III-IV | 11 |
| ZUMA-1 eligible | 2/21 |
| Reasons not eligible for ZUMA-1 | |
| Required bridging therapy | 19 |
| Platelets <75/nL | 6 |
| LVEF <50 | 6 |
| ECOG >1 | 3 |
| CNS disease | 1 |
Numbers indicate the numbers of patients, unless indicated otherwise.
CNS, central nervous system; CRP, C-reactive protein; DLBCL diffuse large B-cell lymphoma, ECOG, Eastern Cooperative Oncology Group; F, female; GCB, germinal center B cell; IL-6, interleukin-6; IPI, international prognostic index; LD, lymphodepletion; LDH, lactate dehydrogenase, LVEF, left ventricular ejection fraction; M, male; MTX, methotrexate; PMBCL, primary mediastinal B-cell lymphoma; PS, performance status; R, Rituximab; R-GemOx, rituximab, gemcitabine, oxaliplatin; R-ICE, rituximab, ifosfamide, carboplatin, etoposide; R-LEAM, rituximab, lomustine, etoposide, cytarabine, melphalan.